XENAZINE Drug Patent Profile

When do Xenazine patents expire, and what generic alternatives are available?

Xenazine is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in XENAZINE is tetrabenazine. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the tetrabenazine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xenazine

A generic version of XENAZINE was approved as tetrabenazine by HETERO LABS LTD V on February 3^rd, 2016.

Summary for XENAZINE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	115
Clinical Trials:	6
Patent Applications:	2,964
Drug Prices:	Drug price information for XENAZINE
What excipients (inactive ingredients) are in XENAZINE?	XENAZINE excipients list
DailyMed Link:	XENAZINE at DailyMed

See drug prices for XENAZINE

Recent Clinical Trials for XENAZINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Texas Health Science Center, Houston	Phase 4
H. Lundbeck A/S	Phase 4
William Ondo, MD	Phase 4

See all XENAZINE clinical trials

Pharmacology for XENAZINE

Drug Class	Vesicular Monoamine Transporter 2 Inhibitor
Mechanism of Action	Vesicular Monoamine Transporter 2 Inhibitors

US Patents and Regulatory Information for XENAZINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	XENAZINE	tetrabenazine	TABLET;ORAL	021894-001	Aug 15, 2008	AB	RX	Yes	No
Bausch	XENAZINE	tetrabenazine	TABLET;ORAL	021894-002	Aug 15, 2008	AB	RX	Yes	Yes

XENAZINE Market Dynamics, Patent Exclusivity, Revenue Trajectory, and Generic Competition

Last updated: September 9, 2026

XENAZINE, the branded form of tetrabenazine, is a mature orphan drug for chorea associated with Huntington's disease. Its U.S. market position has weakened because orphan exclusivity expired in 2015, generic tetrabenazine entered the market, and Teva's longer-acting successor product, AUSTEDO, became the company's commercial focus. XENAZINE remains clinically relevant, but its standalone revenue is not publicly reported and its economic value is substantially below that of AUSTEDO.

What is XENAZINE and how is it used?

XENAZINE contains tetrabenazine, a vesicular monoamine transporter 2 inhibitor. The FDA approved it in August 2008 for chorea associated with Huntington's disease [1].

Attribute	XENAZINE
Active ingredient	Tetrabenazine
Dosage form	Oral tablets
U.S. indication	Chorea associated with Huntington's disease
Initial U.S. approval	Aug. 15, 2008
FDA application	NDA 021894
Original sponsor	Prestwick Pharmaceuticals
Current commercial association	Lundbeck in the U.S.
Pharmacologic class	VMAT2 inhibitor
Primary successor product	AUSTEDO, deutetrabenazine
Generic competition	Tetrabenazine tablets

XENAZINE reduces presynaptic monoamine storage and release. Its pharmacokinetic profile requires dose titration and, in many patients, multiple daily dosing. The label includes boxed-warning-level risks involving depression and suicidality in patients with Huntington's disease, as well as warnings concerning akathisia, parkinsonism, neuroleptic malignant syndrome, QT prolongation, sedation, and interactions involving CYP2D6 [1].

When did XENAZINE lose exclusivity?

XENAZINE lost its principal U.S. market exclusivity in 2015. The product received seven years of orphan-drug exclusivity from the FDA's approval date, placing the end of that period in August 2015 [1][2].

Exclusivity or IP event	Date or status
FDA approval	Aug. 15, 2008
Seven-year orphan exclusivity	Expired in Aug. 2015
Generic tetrabenazine availability	Began after FDA approval of ANDAs, principally from 2015 onward
Core composition-of-matter protection	No longer blocks ordinary generic entry
Current commercial protection	Primarily brand recognition, prescriber familiarity, reimbursement positioning, and manufacturing know-how

Orphan exclusivity prevented FDA approval of a product for the same indication, but it did not create permanent protection against all tetrabenazine products. Once the period ended, ANDA applicants could rely on XENAZINE's safety and efficacy findings, subject to FDA requirements and any enforceable listed patents.

What patents protect XENAZINE?

The core tetrabenazine molecule is old relative to the product's 2008 approval. XENAZINE's commercial protection was therefore driven more by regulatory exclusivity, formulation and dosing claims, labeling rights, and market execution than by a durable composition-of-matter patent.

Public FDA materials identify XENAZINE under NDA 021894 and list the product in the Orange Book. The relevant patent estate has not provided a lasting barrier comparable to the patent protection associated with a newly discovered chemical entity [2].

What formulation patents cover XENAZINE?

XENAZINE is an immediate-release tablet. Its formulation is comparatively simple and lacks the delivery-system complexity found in long-acting injectables, extended-release products, transdermal systems, or device-based products.

The main commercial barriers are:

• FDA-approved labeling for Huntington's disease chorea.
• Dose-titration instructions.
• Safety management for depression, suicidality, CYP2D6 status, and QT risk.
• Manufacturing controls for a potent central-nervous-system active ingredient.
• Physician and patient familiarity.
• Payer and specialty-pharmacy contracting.

These factors can slow substitution but do not normally prevent an approved generic from entering after patent and exclusivity barriers expire.

What method-of-use patents protect XENAZINE?

The original approved indication is chorea associated with Huntington's disease. Method-of-use protection, if listed, is narrower than composition-of-matter protection and can be avoided through a section viii statement or a carved-out label where the applicable legal and regulatory conditions permit.

No widely recognized, currently enforceable method-of-use patent appears to preserve a broad U.S. monopoly for XENAZINE. Huntington's disease chorea is also a narrow indication, which limits the commercial value of any additional indication patent unless it materially expands the treatable population.

What is the Orange Book status of XENAZINE?

XENAZINE is listed in the FDA Orange Book under NDA 021894. The Orange Book identifies approved drug products and relevant patent and exclusivity information used in the ANDA approval process [2].

The practical Orange Book position is mature:

1. The product's orphan exclusivity has expired.
2. Generic tetrabenazine applicants can pursue ANDA approval.
3. Any remaining listed patents must be assessed by claim scope, expiration, certification, and litigation history.
4. Generic applicants can challenge listed patents through Paragraph IV certifications.
5. A generic may enter after patent resolution, settlement, expiration, or a court ruling that removes the relevant barrier.

The commercial significance of an Orange Book listing is therefore limited unless a listed patent has meaningful remaining term and covers a claim that generic applicants cannot readily design around.

Which companies are challenging XENAZINE?

The principal competitive challenge has come from generic tetrabenazine manufacturers rather than from a single high-profile patent challenger. FDA-approved generic tetrabenazine products have been associated with major generic manufacturers, including Teva, Sun Pharmaceutical Industries, and other ANDA sponsors over time.

The more important competitive threat has been therapeutic substitution:

• Generic tetrabenazine reduces price.
• AUSTEDO offers deuterated tetrabenazine with a differentiated dosing profile.
• INGREZZA, valbenazine, competes in the broader VMAT2 inhibitor category, particularly for tardive dyskinesia.
• Payers may prefer lower-cost generic tetrabenazine for eligible Huntington's disease patients.
• Specialists may favor AUSTEDO where dosing convenience, tolerability, or payer coverage supports the choice.

Publicly available information does not establish a current, material Paragraph IV litigation campaign capable of restoring XENAZINE exclusivity.

How does XENAZINE compare with AUSTEDO and INGREZZA?

AUSTEDO is the most important commercial comparator because Teva developed it as a next-generation tetrabenazine product. It contains deutetrabenazine, in which hydrogen atoms are replaced with deuterium. The modification is intended to alter metabolism and support less frequent dosing than conventional tetrabenazine.

Product	Active ingredient	Main U.S. indications	Commercial position
XENAZINE	Tetrabenazine	Huntington's disease chorea	Mature branded product with generic competition
Generic tetrabenazine	Tetrabenazine	Huntington's disease chorea	Low-cost substitute
AUSTEDO	Deutetrabenazine	Huntington's disease chorea and tardive dyskinesia	Teva's growth product
INGREZZA	Valbenazine	Tardive dyskinesia; Huntington's disease chorea under expanded labeling	Major branded VMAT2 competitor

AUSTEDO has a broader commercial platform than XENAZINE because it addresses Huntington's disease chorea and tardive dyskinesia. Tardive dyskinesia has a larger treated population and has supported substantial expansion of the VMAT2 market.

What is the financial trajectory of XENAZINE?

XENAZINE's standalone revenue is not separately disclosed in the public financial reporting of its current commercial owner. That limits precise revenue reconstruction. Public company reporting instead emphasizes the broader VMAT2 franchise, especially AUSTEDO.

The financial trajectory is clear even without product-level revenue:

Period	Financial direction
2008-2014	Branded orphan-drug growth supported by exclusivity and limited treatment alternatives
2015-2018	Revenue pressure from generic entry and the end of orphan exclusivity
2017 onward	Commercial focus shifted toward AUSTEDO
2020-2024	XENAZINE became a mature or declining contributor while AUSTEDO expanded rapidly
Current outlook	Stable niche demand, lower pricing power, and limited standalone growth

Teva reported strong growth for AUSTEDO in its annual filings, with sales reaching approximately $1.4 billion in 2023 and continuing to increase in 2024 [3][4]. Those figures should not be attributed to XENAZINE. They show the value migration within Teva's VMAT2 portfolio from the older tetrabenazine product to the differentiated deutetrabenazine franchise.

XENAZINE's commercial value is now concentrated in:

• Residual branded prescriptions.
• Patients stabilized on the original product.
• Formulary positions that preserve brand access.
• Patients for whom generic substitution is unsuitable or unavailable.
• International or contractual rights, where applicable.

Its revenue exposure is therefore meaningful as a legacy product but immaterial relative to Teva's newer specialty-growth assets.

What licensing deals affect XENAZINE?

XENAZINE originated with Prestwick Pharmaceuticals, which developed the U.S. product and obtained FDA approval. Lundbeck acquired Prestwick in 2009, bringing XENAZINE into Lundbeck's commercial portfolio [5].

The product's corporate history is distinct from Teva's AUSTEDO rights. Teva acquired Auspex Pharmaceuticals in 2015, gaining deutetrabenazine and subsequently commercializing AUSTEDO [6]. That transaction created the strategic shift away from reliance on XENAZINE.

Transaction	Strategic effect
Prestwick development and FDA approval	Established the U.S. XENAZINE franchise
Lundbeck acquisition of Prestwick	Added XENAZINE to Lundbeck's U.S. specialty portfolio
Teva acquisition of Auspex	Added deutetrabenazine and created AUSTEDO
AUSTEDO development	Reduced the long-term strategic importance of XENAZINE

No major recent licensing transaction appears to have materially increased the value of the XENAZINE brand itself.

What generic entry risks exist for XENAZINE?

Generic entry risk is high because the product has lost orphan exclusivity and the active ingredient is established. The principal risks are price erosion, formulary substitution, channel displacement, and reduced physician attention.

Generic launch scenarios

Scenario	Market effect
One generic entrant	Moderate price pressure; brand may retain some share
Several generic entrants	Significant price erosion and rapid share loss
Payer-mandated substitution	Faster conversion from brand to generic
Limited generic supply	Brand retains residual demand and pricing
AUSTEDO preferred by specialists	XENAZINE loses share even without additional generic entrants

Generic conversion may be slower than in high-volume primary-care markets because Huntington's disease is rare and treatment is concentrated among neurologists and specialty pharmacies. That factor limits volume but does not restore exclusivity.

How strong is the XENAZINE patent estate?

The XENAZINE patent estate is weak as a current growth asset. Its principal strengths are regulatory history, physician familiarity, and a narrow specialty market. Its principal weaknesses are expired orphan exclusivity, generic availability, an older active ingredient, limited formulation differentiation, and competition from AUSTEDO and INGREZZA.

Patent-estate factor	Assessment
New chemical entity protection	Weak or expired
Orphan exclusivity	Expired
Formulation differentiation	Limited
Method-of-use protection	Narrow and not a broad current barrier
Generic design-around risk	High
Manufacturing complexity	Moderate
Commercial switching costs	Moderate in stable patients
Long-term growth potential	Low

What patent litigation affects XENAZINE?

XENAZINE does not have a current litigation profile comparable to high-value products protected by active composition patents or complex biologic manufacturing claims. Historical patent and ANDA disputes may have occurred around generic entry, but the central commercial issue is now post-exclusivity competition rather than an unresolved patent blockade.

The litigation risk is more relevant to successor products. AUSTEDO has greater strategic value and a more important patent and exclusivity profile because it is a major growth franchise for Teva. Any challenge to AUSTEDO would have a materially larger financial impact than a challenge to XENAZINE.

What is the FDA regulatory status of XENAZINE?

XENAZINE remains an FDA-approved product for Huntington's disease chorea. Its approval is based on tetrabenazine's established efficacy and safety data, subject to the product label [1].

Regulatory risks include:

• Depression and suicidality in Huntington's disease.
• CYP2D6 genotype and inhibitor interactions.
• QT prolongation.
• Sedation and impaired motor performance.
• Parkinsonism and akathisia.
• Neuroleptic malignant syndrome.
• Dose limitations in poor metabolizers or patients receiving strong CYP2D6 inhibitors.

These risks affect prescribing, monitoring, and payer management. They also create a clinical rationale for selecting newer VMAT2 inhibitors, depending on patient-specific factors.

What geographic coverage does XENAZINE have?

XENAZINE's strongest commercial relevance is in the United States, where it received FDA approval and established the first branded tetrabenazine franchise for Huntington's disease chorea. International markets may use tetrabenazine under different brand names, marketing authorizations, or reimbursement arrangements.

Geographic value is constrained by:

• Low Huntington's disease prevalence.
• Uneven diagnosis rates.
• National reimbursement controls.
• Specialist concentration.
• Availability of generic tetrabenazine.
• Competition from deutetrabenazine and valbenazine where approved.

The U.S. market remains the key reference point for patent, exclusivity, and revenue analysis.

Key Takeaways

• XENAZINE is an FDA-approved tetrabenazine product for Huntington's disease chorea.
• Its seven-year orphan-drug exclusivity expired in August 2015.
• Generic tetrabenazine has materially weakened the brand's pricing power.
• XENAZINE's standalone revenue is not separately disclosed.
• Teva's financial upside is concentrated in AUSTEDO, not XENAZINE.
• AUSTEDO and INGREZZA are the principal branded VMAT2 competitors.
• The XENAZINE patent estate is mature and does not provide a durable broad monopoly.
• Generic entry risk is high, although specialty prescribing and limited patient volume can slow substitution.
• The product remains FDA-approved but is strategically a legacy asset rather than a growth platform.
• The most important commercial trend is migration from conventional tetrabenazine to newer VMAT2 inhibitors.

FAQs About XENAZINE Market and Patent Exclusivity

Is XENAZINE still available in the United States?

Yes. XENAZINE remains an FDA-approved tetrabenazine product, although generic tetrabenazine is also available and may be preferred by payers.

Does XENAZINE have orphan-drug exclusivity?

No. The product's seven-year U.S. orphan exclusivity period expired in August 2015.

Is XENAZINE the same as AUSTEDO?

No. XENAZINE contains tetrabenazine. AUSTEDO contains deutetrabenazine, a chemically modified form designed to support a different pharmacokinetic profile and less frequent dosing.

Can a generic launch without copying the XENAZINE brand?

Yes. An ANDA applicant can seek approval for generic tetrabenazine by relying on the reference product's safety and efficacy findings, subject to applicable patent certifications and labeling requirements.

Which product has greater commercial value, XENAZINE or AUSTEDO?

AUSTEDO has materially greater commercial value because it has a broader indication platform, newer product differentiation, and substantially higher reported franchise revenue.

References

1. U.S. Food and Drug Administration. (2024). Xenazine (tetrabenazine) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Teva Pharmaceutical Industries Ltd. (2024). 2023 annual report.
4. Teva Pharmaceutical Industries Ltd. (2025). 2024 annual report.
5. H. Lundbeck A/S. (2009). Annual report 2009.
6. Teva Pharmaceutical Industries Ltd. (2015). Teva to acquire Auspex Pharmaceuticals.